Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FILCAD: Subcutaneous Filgrastim (Neupogen) to Promote Coronary Collateral Growth
2004-003784-68Phase 2Terminated
- Sponsor
- Inselspital
- Start
- Nov 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing Filgrastim (Neupogen) with Placebo (2 arms). Primary endpoint: Collateral coronary blood flow. Started Nov 2004; status: terminated.
02
Drugs
filgrastim
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2004-003784-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003784-68.